Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_assertion type Assertion NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_head.
- NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_assertion description "[However, there are subgroups of patients with HCV-2, such as those with advanced fibrosis/cirrhosis, in whom SVR rates are still suboptimal, and highly responsive groups in whom SVR rates reach 95%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_provenance.
- NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_assertion evidence source_evidence_literature NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_provenance.
- NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_assertion SIO_000772 23286844 NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_provenance.
- NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_assertion wasDerivedFrom befree-20140225 NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_provenance.
- NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_assertion wasGeneratedBy ECO_0000203 NP850930.RA5kvvUDgxFLriDRhDOCmPY_nK47YZ1Yes-HMYqXawo5A130_provenance.